Evidence map›Paper›PMID 37424036›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Separate Gut Plasma Cell Populations Produce Auto-Antibodies against Transglutaminase 2 and Transglutaminase 3 in Dermatitis Herpetiformis.

Saykat Das, Jorunn Stamnaes, Esko Kemppainen, Kaisa Hervonen, Knut E A Lundin, Naveen Parmar, Frode L Jahnsen, Jørgen Jahnsen, Katri Lindfors, Teea Salmi and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Saykat DasDepartment of Immunology, Oslo University Hospital-Rikshospitalet, Oslo, 0372, Norway.
Jorunn StamnaesDepartment of Immunology, Oslo University Hospital-Rikshospitalet, Oslo, 0372, Norway.
Esko KemppainenCeliac Disease Research Centre, Faculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.
Kaisa HervonenCeliac Disease Research Centre, Faculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.
Knut E A LundinKG Jebsen Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, 0372, Norway.
Naveen ParmarDepartment of Pathology, University of Oslo and Institute of Clinical Medicine, Oslo University Hospital-Rikshospitalet, Oslo, 0372, Norway.
Frode L JahnsenDepartment of Pathology, University of Oslo and Institute of Clinical Medicine, Oslo University Hospital-Rikshospitalet, Oslo, 0372, Norway.
Jørgen JahnsenDepartment of Gastroenterology, Akershus University Hospital, Lørenskog, 1478, Norway.
Katri LindforsCeliac Disease Research Centre, Faculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.
Teea SalmiCeliac Disease Research Centre, Faculty of Medicine and Health Technology, Tampere University, Tampere, 33520, Finland.
Rasmus IversenDepartment of Immunology, Oslo University Hospital-Rikshospitalet, Oslo, 0372, Norway.
Ludvig M SollidDepartment of Immunology, Oslo University Hospital-Rikshospitalet, Oslo, 0372, Norway.ORCID 0000-0001-8860-704X
Oslo University Hospital · NOTampere University of Applied Sciences · FIAkershus University Hospital · NO

Funding

Academy of Finland 347471Academy of Finland 347473Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9AB068Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9AC088Sigrid Juselius Foundation 8069South-Eastern Norway Regional Health Authority 2020027Stiftelsen KG Jebsen SKGJ-MED-017University of Oslo World-Leading Research Program on Human Immunology WL-IMMUNOLOGY
6 · The paper itself

Abstract

Dermatitis herpetiformis (DH) is an inflammatory skin disorder often considered as an extra intestinal manifestation of celiac disease (CeD). Hallmarks of CeD and DH are auto-antibodies to transglutaminase 2 (TG2) and transglutaminase 3 (TG3), respectively. DH patients have auto-antibodies reactive with both transglutaminase enzymes. Here it is reported that in DH both gut plasma cells and serum auto-antibodies are specific for either TG2 or TG3 with no TG2-TG3 cross reactivity. By generating monoclonal antibodies from TG3-specific duodenal plasma cells of DH patients, three conformational epitope groups are defined. Both TG2-specific and TG3-specific gut plasma cells have few immunoglobulin (Ig) mutations, and the two transglutaminase-reactive populations show distinct selection of certain heavy and light chain V-genes. Mass spectrometry analysis of TG3-specific serum IgA corroborates preferential usage of IGHV2-5 in combination with IGKV4-1. Collectively, these results demonstrate parallel induction of anti-TG2 and anti-TG3 auto-antibody responses involving separate B-cell populations in DH patients.

Indexed as

Celiac DiseaseDermatitis HerpetiformisHumansImmunoglobulin APlasma CellsProtein Glutamine gamma Glutamyltransferase 2TransglutaminasesImmunoglobulin AProtein Glutamine gamma Glutamyltransferase 2TGM2 protein, humanTGM3 protein, humanTransglutaminasesauto-antibodiesceliac diseasecross reactivitydermatitis herpetiformistransglutaminase 2transglutaminase 3

Identifiers

PMID37424036
PMCPMC10477854
OpenAlexW4383711393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.